(Commission File Number) | (IRS Employer Identification No.) | ||||
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Exhibit Number | Description | |||||||
104 | Cover Page Interactive Data File - the cover page iXBRL tags are embedded within the Inline XBRL document |
ENCOMPASS HEALTH CORPORATION | ||||||||
By: | /S/ DOUGLAS E. COLTHARP | |||||||
Name: | Douglas E. Coltharp | |||||||
Title: | Executive Vice President and Chief Financial Officer |
Media Contact | October 26, 2022 | ||||
Casey Winger, 205 447-6410 | |||||
casey.winger@encompasshealth.com | |||||
Investor Relations Contact | |||||
Mark Miller, 205 970-5860 | |||||
mark.miller@encompasshealth.com |
Growth | |||||||||||||||||||||||
Q3 2022 | Q3 2021 | Dollars | Percent | ||||||||||||||||||||
(In Millions, Except Per Share Data) | |||||||||||||||||||||||
Net operating revenue | $ | 1,089.5 | $ | 1,010.8 | $ | 78.7 | 7.8 | % | |||||||||||||||
Income from continuing operations attributable to Encompass Health per diluted share | 0.63 | 0.76 | (0.13) | (17.1) | % | ||||||||||||||||||
Adjusted earnings per share | 0.67 | 0.76 | (0.09) | (11.8) | % | ||||||||||||||||||
Cash flows provided by operating activities | 70.1 | 177.6 | (107.5) | (60.5) | % | ||||||||||||||||||
Adjusted EBITDA | 195.3 | 199.3 | (4.0) | (2.0) | % | ||||||||||||||||||
Adjusted free cash flow | 26.6 | 87.7 | (61.1) | (69.7) | % | ||||||||||||||||||
Nine Months Ended September 30, | |||||||||||||||||||||||
2022 | 2021 | ||||||||||||||||||||||
Cash flows provided by operating activities | $ | 533.6 | $ | 592.0 | $ | (58.4) | (9.9) | % | |||||||||||||||
Adjusted free cash flow | 294.1 | 302.0 | (7.9) | (2.6) | % |
1 |
% of Revenue | % of Revenue | |||||||||||||||||||||||||
(In Millions) | Q3 2022 | Q3 2021 | ||||||||||||||||||||||||
Net operating revenue | $ | 1,089.5 | $ | 1,010.8 | ||||||||||||||||||||||
% Change | 7.8 | % | ||||||||||||||||||||||||
Salaries and benefits | (605.6) | (55.6) | % | (537.0) | (53.1) | % | ||||||||||||||||||||
Hospital operating expenses | (236.6) | (21.7) | % | (217.6) | (21.5) | % | ||||||||||||||||||||
General and administrative expenses | (32.0) | (2.9) | % | (32.2) | (3.2) | % | ||||||||||||||||||||
Other income | 0.9 | 0.7 | ||||||||||||||||||||||||
Equity in nonconsolidated affiliates | 0.7 | 0.9 | ||||||||||||||||||||||||
Noncontrolling interests in continuing operations | (21.6) | (26.3) | ||||||||||||||||||||||||
Adjusted EBITDA | $ | 195.3 | $ | 199.3 | ||||||||||||||||||||||
% Change | (2.0) | % | ||||||||||||||||||||||||
(Actual Amounts) | ||||||||||||||||||||||||||
Discharges | 53,743 | 49,983 | ||||||||||||||||||||||||
% Change | 7.5 | % | ||||||||||||||||||||||||
Same-store discharge growth | 4.1 | % | ||||||||||||||||||||||||
Net patient revenue per discharge | $ | 19,809 | $ | 19,681 | ||||||||||||||||||||||
% Change | 0.7 | % |
Prior | Updated | |||||||
2022 Guidance Ranges | 2022 Guidance Ranges | |||||||
provided August 1, 2022 | provided October 26, 2022 | |||||||
(In Millions, Except Per Share Data) | ||||||||
Net operating revenue | $4,250 to $4,300 | $4,320 to $4,350 | ||||||
Adjusted EBITDA | $820 to $840 | $800 to $820 | ||||||
Adjusted earnings per share from continuing operations attributable to Encompass Health | $2.77 to $2.91 | $2.71 to $2.86 |
2 |
3 |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
2022 | 2021 | 2022 | 2021 | ||||||||||||||||||||
(In Millions, Except Per Share Data) | |||||||||||||||||||||||
Net operating revenues | $ | 1,089.5 | $ | 1,010.8 | $ | 3,211.3 | $ | 2,972.4 | |||||||||||||||
Operating expenses: | |||||||||||||||||||||||
Salaries and benefits | 605.6 | 537.0 | 1,778.9 | 1,554.8 | |||||||||||||||||||
Other operating expenses | 172.0 | 151.4 | 500.3 | 442.2 | |||||||||||||||||||
Occupancy costs | 12.4 | 14.5 | 41.6 | 44.5 | |||||||||||||||||||
Supplies | 51.1 | 46.7 | 148.2 | 136.0 | |||||||||||||||||||
General and administrative expenses | 37.9 | 38.9 | 111.5 | 123.7 | |||||||||||||||||||
Depreciation and amortization | 62.1 | 55.5 | 180.3 | 162.9 | |||||||||||||||||||
Total operating expenses | 941.1 | 844.0 | 2,760.8 | 2,464.1 | |||||||||||||||||||
Loss on early extinguishment of debt | — | — | 1.4 | 1.0 | |||||||||||||||||||
Interest expense and amortization of debt discounts and fees | 38.2 | 39.9 | 138.2 | 124.3 | |||||||||||||||||||
Other expense (income) | 3.6 | (0.5) | 13.6 | (4.8) | |||||||||||||||||||
Equity in net income of nonconsolidated affiliates | (0.7) | (0.9) | (2.6) | (2.5) | |||||||||||||||||||
Income from continuing operations before income tax expense | 107.3 | 128.3 | 299.9 | 390.3 | |||||||||||||||||||
Provision for income tax expense | 21.8 | 26.2 | 68.2 | 79.4 | |||||||||||||||||||
Income from continuing operations | 85.5 | 102.1 | 231.7 | 310.9 | |||||||||||||||||||
(Loss) income from discontinued operations, net of tax | (18.5) | 24.6 | 16.7 | 90.6 | |||||||||||||||||||
Net and comprehensive income | 67.0 | 126.7 | 248.4 | 401.5 | |||||||||||||||||||
Less: Net income attributable to noncontrolling interests included in continuing operations | (21.6) | (26.3) | (65.5) | (79.6) | |||||||||||||||||||
Less: Net income attributable to noncontrolling interests included in discontinued operations | — | (0.4) | (1.3) | (1.3) | |||||||||||||||||||
Less: Net and comprehensive income attributable to noncontrolling interests | (21.6) | (26.7) | (66.8) | (80.9) | |||||||||||||||||||
Net and comprehensive income attributable to Encompass Health | $ | 45.4 | $ | 100.0 | $ | 181.6 | $ | 320.6 | |||||||||||||||
Weighted average common shares outstanding: | |||||||||||||||||||||||
Basic | 99.2 | 99.0 | 99.2 | 99.0 | |||||||||||||||||||
Diluted | 100.5 | 100.2 | 100.3 | 100.1 | |||||||||||||||||||
Earnings per common share: | |||||||||||||||||||||||
Basic earnings per share attributable to Encompass Health common shareholders: | |||||||||||||||||||||||
Continuing operations | $ | 0.64 | $ | 0.76 | $ | 1.67 | $ | 2.32 | |||||||||||||||
Discontinued operations | (0.19) | 0.24 | 0.15 | 0.90 | |||||||||||||||||||
Net income | $ | 0.45 | $ | 1.00 | $ | 1.82 | $ | 3.22 | |||||||||||||||
Diluted earnings per share attributable to Encompass Health common shareholders: | |||||||||||||||||||||||
Continuing operations | $ | 0.63 | $ | 0.76 | $ | 1.66 | $ | 2.31 | |||||||||||||||
Discontinued operations | (0.18) | 0.24 | 0.15 | 0.89 | |||||||||||||||||||
Net income | $ | 0.45 | $ | 1.00 | $ | 1.81 | $ | 3.20 | |||||||||||||||
Amounts attributable to Encompass Health common shareholders: | |||||||||||||||||||||||
Income from continuing operations | $ | 63.9 | $ | 75.8 | $ | 166.2 | $ | 231.3 | |||||||||||||||
(Loss) income from discontinued operations, net of tax | (18.5) | 24.2 | 15.4 | 89.3 | |||||||||||||||||||
Net income attributable to Encompass Health | $ | 45.4 | $ | 100.0 | $ | 181.6 | $ | 320.6 |
4 |
September 30, 2022 | December 31, 2021 | ||||||||||
(In Millions) | |||||||||||
Assets | |||||||||||
Current assets: | |||||||||||
Cash and cash equivalents | $ | 59.8 | $ | 49.4 | |||||||
Restricted cash | 44.3 | 62.5 | |||||||||
Accounts receivable | 500.1 | 515.8 | |||||||||
Other current assets | 129.6 | 114.9 | |||||||||
Current assets of discontinued operations | — | 178.8 | |||||||||
Total current assets | 733.8 | 921.4 | |||||||||
Property and equipment, net | 2,807.4 | 2,581.2 | |||||||||
Operating lease right-of-use assets | 195.7 | 193.7 | |||||||||
Goodwill | 1,247.4 | 1,237.0 | |||||||||
Intangible assets, net | 284.9 | 158.4 | |||||||||
Other long-term assets | 206.6 | 230.0 | |||||||||
Noncurrent assets of discontinued operations | 0.1 | 1,543.2 | |||||||||
Total assets | $ | 5,475.9 | $ | 6,864.9 | |||||||
Liabilities and Shareholders’ Equity | |||||||||||
Current liabilities: | |||||||||||
Current portion of long-term debt | $ | 26.2 | $ | 37.8 | |||||||
Current operating lease liabilities | 22.7 | 23.5 | |||||||||
Accounts payable | 134.1 | 134.0 | |||||||||
Accrued expenses and other current liabilities | 421.6 | 421.1 | |||||||||
Current liabilities of discontinued operations | 0.1 | 132.4 | |||||||||
Total current liabilities | 604.7 | 748.8 | |||||||||
Long-term debt, net of current portion | 2,719.0 | 3,240.5 | |||||||||
Long-term operating lease liabilities | 183.3 | 179.6 | |||||||||
Deferred income tax liabilities | 46.7 | 23.3 | |||||||||
Other long-term liabilities | 174.0 | 172.7 | |||||||||
Noncurrent liabilities of discontinued operations | 0.4 | 100.8 | |||||||||
3,728.1 | 4,465.7 | ||||||||||
Commitments and contingencies | |||||||||||
Redeemable noncontrolling interests | 37.8 | 42.2 | |||||||||
Shareholders’ equity: | |||||||||||
Encompass Health shareholders’ equity | 1,217.0 | 1,911.3 | |||||||||
Noncontrolling interests | 493.0 | 445.7 | |||||||||
Total shareholders’ equity | 1,710.0 | 2,357.0 | |||||||||
Total liabilities and shareholders’ equity | $ | 5,475.9 | $ | 6,864.9 |
5 |
Nine Months Ended September 30, | |||||||||||
2022 | 2021 | ||||||||||
(In Millions) | |||||||||||
Cash flows from operating activities: | |||||||||||
Net income | $ | 248.4 | $ | 401.5 | |||||||
Income from discontinued operations, net of tax | (16.7) | (90.6) | |||||||||
Adjustments to reconcile net income to net cash provided by operating activities— | |||||||||||
Depreciation and amortization | 180.3 | 162.9 | |||||||||
Loss on early extinguishment of debt | 1.4 | 1.0 | |||||||||
Equity in net income of nonconsolidated affiliates | (2.6) | (2.5) | |||||||||
Distributions from nonconsolidated affiliates | 3.7 | 2.4 | |||||||||
Stock-based compensation | 21.1 | 19.6 | |||||||||
Deferred tax (benefit) expense | (7.7) | 1.6 | |||||||||
Realized loss (gain) on sale of investments | 16.5 | (1.8) | |||||||||
Other, net | 9.7 | 4.2 | |||||||||
Change in assets and liabilities, net of acquisitions— | |||||||||||
Accounts receivable | 22.4 | (10.9) | |||||||||
Other assets | 5.0 | (26.5) | |||||||||
Accounts payable | (0.3) | 9.7 | |||||||||
Accrued payroll | (9.3) | 16.0 | |||||||||
Accrued interest payable | (20.7) | (23.1) | |||||||||
Other liabilities | 26.4 | (5.0) | |||||||||
Net cash provided by operating activities of discontinued operations | 56.0 | 133.5 | |||||||||
Total adjustments | 301.9 | 281.1 | |||||||||
Net cash provided by operating activities | 533.6 | 592.0 | |||||||||
Cash flows from investing activities: | |||||||||||
Acquisitions of businesses, net of cash acquired | — | (1.1) | |||||||||
Purchases of property and equipment | (374.9) | (332.3) | |||||||||
Additions to capitalized software costs | (7.5) | (11.9) | |||||||||
Proceeds from disposal of assets | 5.9 | 17.6 | |||||||||
Purchase of restricted investments | (25.1) | (8.3) | |||||||||
Other, net | (15.4) | (10.0) | |||||||||
Net cash used in investing activities of discontinued operations | (3.6) | (99.6) | |||||||||
Net cash used in investing activities | (420.6) | (445.6) | |||||||||
6 |
Nine Months Ended September 30, | |||||||||||
2022 | 2021 | ||||||||||
(In Millions) | |||||||||||
Cash flows from financing activities: | |||||||||||
Principal payments on debt, including pre-payments | (345.3) | (210.9) | |||||||||
Borrowings on revolving credit facility | 180.0 | 145.0 | |||||||||
Payments on revolving credit facility | (340.0) | (55.0) | |||||||||
Principal payments under finance lease obligations | (14.3) | (13.0) | |||||||||
Debt amendment costs | (21.6) | — | |||||||||
Taxes paid on behalf of employees for shares withheld | (7.2) | (14.6) | |||||||||
Contributions from noncontrolling interests of consolidated affiliates | 55.1 | 36.1 | |||||||||
Dividends paid on common stock | (84.1) | (84.5) | |||||||||
Distributions paid to noncontrolling interests of consolidated affiliates | (68.2) | (76.2) | |||||||||
Other, net | 0.3 | (0.1) | |||||||||
Net cash provided by (used in) financing activities of discontinued operations | 516.1 | (9.2) | |||||||||
Net cash used in financing activities | (129.2) | (282.4) | |||||||||
Decrease in cash, cash equivalents, and restricted cash | (16.2) | (136.0) | |||||||||
Cash, cash equivalents, and restricted cash at beginning of period | 120.3 | 310.9 | |||||||||
Cash, cash equivalents, and restricted cash at end of period | $ | 104.1 | $ | 174.9 | |||||||
Reconciliation of Cash, Cash Equivalents, and Restricted Cash | |||||||||||
Cash and cash equivalents at beginning of period | $ | 49.4 | $ | 185.6 | |||||||
Restricted cash at beginning of period | 62.5 | 63.9 | |||||||||
Restricted cash included in other long-term assets at beginning of period | 0.4 | 21.5 | |||||||||
Cash, cash equivalents, and restricted cash in discontinued operations at beginning of period | 8.0 | 39.9 | |||||||||
Cash, cash equivalents, and restricted cash at beginning of period | $ | 120.3 | $ | 310.9 | |||||||
Cash and cash equivalents at end of period | $ | 59.8 | $ | 65.7 | |||||||
Restricted cash at end of period | 44.3 | 73.6 | |||||||||
Restricted cash included in other long-term assets at end of period | — | 4.2 | |||||||||
Cash, cash equivalents, and restricted cash in discontinued operations at end of period | — | 31.4 | |||||||||
Cash, cash equivalents, and restricted cash at end of period | $ | 104.1 | $ | 174.9 | |||||||
7 |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
2022 | 2021 | 2022 | 2021 | ||||||||||||||||||||
(In Millions, Except Per Share Data) | |||||||||||||||||||||||
Adjusted EBITDA | $ | 195.3 | $ | 199.3 | $ | 586.6 | $ | 616.5 | |||||||||||||||
Depreciation and amortization | (62.1) | (55.5) | (180.3) | (162.9) | |||||||||||||||||||
Interest expense and amortization of debt discounts and fees | (38.2) | (39.9) | (138.2) | (124.3) | |||||||||||||||||||
Stock-based compensation | (7.3) | (6.6) | (21.1) | (19.6) | |||||||||||||||||||
Gain (loss) on disposal or impairment of assets | 1.1 | 5.0 | (2.4) | 1.7 | |||||||||||||||||||
88.8 | 102.3 | 244.6 | 311.4 | ||||||||||||||||||||
Items not indicative of ongoing operating performance: | |||||||||||||||||||||||
Loss on early extinguishment of debt | — | — | (1.4) | (1.0) | |||||||||||||||||||
Change in fair market value of equity securities | (3.1) | (0.3) | (8.8) | 0.3 | |||||||||||||||||||
Pre-tax income | 85.7 | 102.0 | 234.4 | 310.7 | |||||||||||||||||||
Income tax expense | (21.8) | (26.2) | (68.2) | (79.4) | |||||||||||||||||||
Income from continuing operations (1) | $ | 63.9 | $ | 75.8 | $ | 166.2 | $ | 231.3 | |||||||||||||||
Basic shares | 99.2 | 99.0 | 99.2 | 99.0 | |||||||||||||||||||
Diluted shares | 100.5 | 100.2 | 100.3 | 100.1 | |||||||||||||||||||
Basic earnings per share (1) | $ | 0.64 | $ | 0.76 | $ | 1.67 | $ | 2.32 | |||||||||||||||
Diluted earnings per share (1) | $ | 0.63 | $ | 0.76 | $ | 1.66 | $ | 2.31 |
8 |
Q3 | 9 Months | ||||||||||||||||||||||
2022 | 2021 | 2022 | 2021 | ||||||||||||||||||||
Earnings per share, as reported | $ | 0.63 | $ | 0.76 | $ | 1.66 | $ | 2.31 | |||||||||||||||
Adjustments, net of tax: | |||||||||||||||||||||||
Bondholder consent fees associated with Enhabit distribution | — | — | 0.15 | — | |||||||||||||||||||
Income tax adjustments | 0.01 | — | 0.08 | (0.03) | |||||||||||||||||||
Loss on early extinguishment of debt | — | — | 0.01 | 0.01 | |||||||||||||||||||
Change in fair market value of equity securities | 0.02 | — | 0.06 | — | |||||||||||||||||||
Adjusted earnings per share* | $ | 0.67 | $ | 0.76 | $ | 1.97 | $ | 2.28 |
9 |
For the Three Months Ended September 30, 2022 | |||||||||||||||||||||||
Adjustments | |||||||||||||||||||||||
As Reported | Income Tax Adjustments | Change in Fair Market Value of Equity Securities | As Adjusted | ||||||||||||||||||||
(In Millions, Except Per Share Amounts) | |||||||||||||||||||||||
Adjusted EBITDA* | $ | 195.3 | $ | — | $ | — | $ | 195.3 | |||||||||||||||
Depreciation and amortization | (62.1) | — | — | (62.1) | |||||||||||||||||||
Interest expense and amortization of debt discounts and fees | (38.2) | — | — | (38.2) | |||||||||||||||||||
Stock-based compensation | (7.3) | — | — | (7.3) | |||||||||||||||||||
Gain on disposal or impairment of assets | 1.1 | — | — | 1.1 | |||||||||||||||||||
Change in fair market value of equity securities | (3.1) | — | 3.1 | — | |||||||||||||||||||
Income from continuing operations before income tax expense | 85.7 | — | 3.1 | 88.8 | |||||||||||||||||||
Provision for income tax expense | (21.8) | 1.3 | (0.8) | (21.3) | |||||||||||||||||||
Income from continuing operations attributable to Encompass Health | $ | 63.9 | $ | 1.3 | $ | 2.3 | $ | 67.5 | |||||||||||||||
Diluted earnings per share from continuing operations** | $ | 0.63 | $ | 0.01 | $ | 0.02 | $ | 0.67 | |||||||||||||||
Diluted shares used in calculation | 100.5 |
10 |
For the Three Months Ended September 30, 2021 | |||||||||||||||||||||||
Adjustments | |||||||||||||||||||||||
As Reported | Income Tax Adjustments | Change in Fair Market Value of Equity Securities | As Adjusted | ||||||||||||||||||||
(In Millions, Except Per Share Amounts) | |||||||||||||||||||||||
Adjusted EBITDA* | $ | 199.3 | $ | — | $ | — | $ | 199.3 | |||||||||||||||
Depreciation and amortization | (55.5) | — | — | (55.5) | |||||||||||||||||||
Interest expense and amortization of debt discounts and fees | (39.9) | — | — | (39.9) | |||||||||||||||||||
Stock-based compensation | (6.6) | — | — | (6.6) | |||||||||||||||||||
Gain on disposal or impairment of assets | 5.0 | — | — | 5.0 | |||||||||||||||||||
Change in fair market value of equity securities | (0.3) | — | 0.3 | — | |||||||||||||||||||
Income from continuing operations before income tax expense | 102.0 | — | 0.3 | 102.3 | |||||||||||||||||||
Provision for income tax expense | (26.2) | (0.2) | (0.1) | (26.5) | |||||||||||||||||||
Income from continuing operations attributable to Encompass Health | $ | 75.8 | $ | (0.2) | $ | 0.2 | $ | 75.8 | |||||||||||||||
Diluted earnings per share from continuing operations** | $ | 0.76 | $ | — | $ | — | $ | 0.76 | |||||||||||||||
Diluted shares used in calculation | 100.2 |
11 |
For the Nine Months Ended September 30, 2022 | |||||||||||||||||||||||||||||||||||
Adjustments | |||||||||||||||||||||||||||||||||||
As Reported | Loss on Early Extinguishment of Debt | Income Tax Adjustments | Bondholder Consent Fees Associated with Enhabit Distribution | Change in Fair Market Value of Equity Securities | As Adjusted | ||||||||||||||||||||||||||||||
(In Millions, Except Per Share Amounts) | |||||||||||||||||||||||||||||||||||
Adjusted EBITDA* | $ | 586.6 | $ | — | $ | — | $ | — | $ | — | $ | 586.6 | |||||||||||||||||||||||
Depreciation and amortization | (180.3) | — | — | — | — | (180.3) | |||||||||||||||||||||||||||||
Interest expense and amortization of debt discounts and fees | (138.2) | — | — | 20.5 | — | (117.7) | |||||||||||||||||||||||||||||
Stock-based compensation | (21.1) | — | — | — | — | (21.1) | |||||||||||||||||||||||||||||
Loss on disposal or impairment of assets | (2.4) | — | — | — | — | (2.4) | |||||||||||||||||||||||||||||
Loss on early extinguishment of debt | (1.4) | 1.4 | — | — | — | — | |||||||||||||||||||||||||||||
Change in fair market value of equity securities | (8.8) | — | — | — | 8.8 | — | |||||||||||||||||||||||||||||
Income from continuing operations before income tax expense | 234.4 | 1.4 | — | 20.5 | 8.8 | 265.1 | |||||||||||||||||||||||||||||
Provision for income tax expense | (68.2) | (0.4) | 8.5 | (5.3) | (2.3) | (67.7) | |||||||||||||||||||||||||||||
Income from continuing operations attributable to Encompass Health | $ | 166.2 | $ | 1.0 | $ | 8.5 | $ | 15.2 | $ | 6.5 | $ | 197.4 | |||||||||||||||||||||||
Diluted earnings per share from continuing operations** | $ | 1.66 | $ | 0.01 | $ | 0.08 | $ | 0.15 | $ | 0.06 | $ | 1.97 | |||||||||||||||||||||||
Diluted shares used in calculation | 100.3 |
12 |
For the Nine Months Ended September 30, 2021 | |||||||||||||||||||||||||||||
Adjustments | |||||||||||||||||||||||||||||
As Reported | Loss on Early Extinguishment of Debt | Income Tax Adjustments | Change in Fair Market Value of Equity Securities | As Adjusted | |||||||||||||||||||||||||
(In Millions, Except Per Share Amounts) | |||||||||||||||||||||||||||||
Adjusted EBITDA* | $ | 616.5 | $ | — | $ | — | $ | — | $ | 616.5 | |||||||||||||||||||
Depreciation and amortization | (162.9) | — | — | — | (162.9) | ||||||||||||||||||||||||
Interest expense and amortization of debt discounts and fees | (124.3) | — | — | — | (124.3) | ||||||||||||||||||||||||
Stock-based compensation | (19.6) | — | — | — | (19.6) | ||||||||||||||||||||||||
Gain on disposal or impairment of assets | 1.7 | — | — | — | 1.7 | ||||||||||||||||||||||||
Loss on early extinguishment of debt | (1.0) | 1.0 | — | — | — | ||||||||||||||||||||||||
Change in fair market value of equity securities | 0.3 | — | — | (0.3) | — | ||||||||||||||||||||||||
Income from continuing operations before income tax expense | 310.7 | 1.0 | — | (0.3) | 311.4 | ||||||||||||||||||||||||
Provision for income tax expense | (79.4) | (0.3) | (3.3) | 0.1 | (82.9) | ||||||||||||||||||||||||
Income from continuing operations attributable to Encompass Health | $ | 231.3 | $ | 0.7 | $ | (3.3) | $ | (0.2) | $ | 228.5 | |||||||||||||||||||
Diluted earnings per share from continuing operations** | $ | 2.31 | $ | 0.01 | $ | (0.03) | $ | — | $ | 2.28 | |||||||||||||||||||
Diluted shares used in calculation | 100.1 |
13 |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
2022 | 2021 | 2022 | 2021 | ||||||||||||||||||||
(In Millions) | |||||||||||||||||||||||
Net income | $ | 67.0 | $ | 126.7 | $ | 248.4 | $ | 401.5 | |||||||||||||||
Loss (income) from discontinued operations, net of tax, attributable to Encompass Health | 18.5 | (24.6) | (16.7) | (90.6) | |||||||||||||||||||
Net income attributable to noncontrolling interests included in continuing operations | (21.6) | (26.3) | (65.5) | (79.6) | |||||||||||||||||||
Provision for income tax expense | 21.8 | 26.2 | 68.2 | 79.4 | |||||||||||||||||||
Interest expense and amortization of debt discounts and fees | 38.2 | 39.9 | 138.2 | 124.3 | |||||||||||||||||||
Depreciation and amortization | 62.1 | 55.5 | 180.3 | 162.9 | |||||||||||||||||||
Loss on early extinguishment of debt | — | — | 1.4 | 1.0 | |||||||||||||||||||
(Gain) loss on disposal or impairment of assets | (1.1) | (5.0) | 2.4 | (1.7) | |||||||||||||||||||
Stock-based compensation | 7.3 | 6.6 | 21.1 | 19.6 | |||||||||||||||||||
Change in fair market value of equity securities | 3.1 | 0.3 | 8.8 | (0.3) | |||||||||||||||||||
Adjusted EBITDA | $ | 195.3 | $ | 199.3 | $ | 586.6 | $ | 616.5 |
14 |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
2022 | 2021 | 2022 | 2021 | ||||||||||||||||||||
(In Millions) | |||||||||||||||||||||||
Net cash provided by operating activities | $ | 70.1 | $ | 177.6 | $ | 533.6 | $ | 592.0 | |||||||||||||||
Interest expense and amortization of debt discounts and fees | 38.2 | 39.9 | 138.2 | 124.3 | |||||||||||||||||||
(Loss) gain on sale of investments, excluding impairments | (4.6) | (0.3) | (16.5) | 1.8 | |||||||||||||||||||
Equity in net income of nonconsolidated affiliates | 0.7 | 0.9 | 2.6 | 2.5 | |||||||||||||||||||
Net income attributable to noncontrolling interests in continuing operations | (21.6) | (26.3) | (65.5) | (79.6) | |||||||||||||||||||
Amortization of debt-related items | (2.6) | (1.8) | (7.4) | (5.8) | |||||||||||||||||||
Distributions from nonconsolidated affiliates | (0.8) | (0.8) | (3.7) | (2.4) | |||||||||||||||||||
Current portion of income tax expense | 23.0 | 28.1 | 75.9 | 77.8 | |||||||||||||||||||
Change in assets and liabilities | 69.9 | 17.6 | (23.5) | 39.8 | |||||||||||||||||||
Cash used in (provided by) operating activities of discontinued operations | 19.9 | (35.7) | (56.0) | (133.5) | |||||||||||||||||||
Change in fair market value of equity securities | 3.1 | 0.3 | 8.8 | (0.3) | |||||||||||||||||||
Other | — | (0.2) | 0.1 | (0.1) | |||||||||||||||||||
Adjusted EBITDA | $ | 195.3 | $ | 199.3 | $ | 586.6 | $ | 616.5 |
15 |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
2022 | 2021 | 2022 | 2021 | ||||||||||||||||||||
(In Millions) | |||||||||||||||||||||||
Net cash provided by operating activities | $ | 70.1 | $ | 177.6 | $ | 533.6 | $ | 592.0 | |||||||||||||||
Impact of discontinued operations | 19.9 | (35.7) | (56.0) | (133.5) | |||||||||||||||||||
Net cash provided by operating activities of continuing operations | 90.0 | 141.9 | 477.6 | 458.5 | |||||||||||||||||||
Capital expenditures for maintenance | (56.2) | (30.3) | (127.6) | (81.0) | |||||||||||||||||||
Distributions paid to noncontrolling interests of consolidated affiliates | (22.3) | (24.8) | (68.2) | (76.2) | |||||||||||||||||||
Items not indicative of ongoing operating performance: | |||||||||||||||||||||||
Transaction costs and related assumed liabilities | 15.1 | 0.9 | 12.3 | 0.7 | |||||||||||||||||||
Adjusted free cash flow | $ | 26.6 | $ | 87.7 | $ | 294.1 | $ | 302.0 |
16 |
17 |
18 |
=C"75.P)Y_E15-[R4'[HHIW$8OQ-_Y'F[_ -Q?YFN1KKOB;_R/
M-W_N+_,UR-?8X;^#'T1Z,/A04445N6%%%% ""EI!2T""BBB@ HHHH ****!!
M1110!;TW3KG5;^*RM(R\TK!0/3GJ?:O7=)^$&G1VZG4KAYI3R53*@?CFL[X,
MV,3R:C>MS(FQ%]L[LUM?$CQG?^'9+>ST\(LDJ;VD;.0,D8'/M7D8JO6J5_84
M78YIRDY D;?80'^[Q^M:.E^&8=72ZO"
M=LB@*55 0_R%<5HI862%" P;(S726\\OV2+/_62GM[#WKUGP[<2W/PO
M\R9V=_LL@W,O>/$Z+J/P]E:Y W-'&Q)]=ZUO.5;#58N4^92$
M>?\ @OX<'7+0:AJ,C16S?ZM%ZMSU^E=!??#+P_4%1AL8Y(']:E\*_#2WO-+34]8G:..1=RQ@@8'J373?
M$UC_ ,(0&)RD6X0!980S*>QQFLY3Q.#J
M1YY73$W*#U9\O44YP%<@'(!IM>Z;A7JWP=NK>V35//GCCSY>-[ 9^]7E-.21
MX\['9<^AQ6.(H^VING>UR9+F5CZ"U?PUX4UN_:]O9XVF8 $B916;/X&\%I;2
MLDB;@A(_?KUQ7B/VB?\ Y[2?]]&E^T38_P!=)_WT:XHX"I%655V,^1KJ>G_"
MN:ULM;UE'FCCC!VH78#(#&N3\?RQS>,;UXW5U+'!4Y'4US2R.A)5V4GK@XI&
M9F.6))]2:ZH8?EK.K?=#Y=;GN/AB^M$^&/E/N4\8P>'?#M]87&AW"&]MV4O'&P8$ ]R.AKSY;RY5
M=JW$H'H'-1EF8Y8DGU)HI82I%KGJ-I=!
"JGMT_^O7A^A^&9_P#A,M1U.X9DCBN)/+XQO)/7]34U)*.K(IQV$TH2:23>@/<8'^%,^(GA'3K*WN-:@N
)_^@D_YG_&C_A8'B?_
M *"3_F?\:+!S(^B:*^=O^$_\3_\ 02D_,_XTO_"?^)_^@D_YG_&BP
BCO100P[TM)WI:"&%**2E%(AA11100P%+2"EH(8
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M\M B';2A:?BE I"&[:4"GXI0*!C,4[%."TH% #<4T\5+BJ=TT\4D
ZNI%: N QWAN/:J(CAC8B95DSU;&<4UK:-@?)
MD=,]!GBL*DKQT.JE#E;-;[7#$A:60 =JQK_5K6XMY3%\QC!ZC S5+4;>X2W8
MRNQ7HK+6AH&C6\ML([@!@5&023S4T[:-ERO;0XQ5DC602%06!.!VK/#$D@FM
M/4;233M;N+:1LCJI]164WRR./NNB+6T1DD;:
MKX49[\UQGAYO]'C_ .NE=F#Y]GMD (5L#]*X:C?M-/,ZH:Q1+*S!%?*^6PRI
M!%9-QJMG#_K)U7Z@U9DQ% P7.U0<#-<)KMX9TA/E#.2.!CTK#2]CKITY25^Q
MTO\ ;%G,&\F0R8Z[5-0)J<,UT8%#!P-W([5B>&@V;D%1T'3\:TM+L)K_ ,0N
MD:':$PS>G2JY&W9&=-Z/!<
MH>064?X5.AJ=/&+&),OXBB738W0[)4!QQ\QK$C@5!S:LG^XU/F98X&_>3K
MQ]218T4L[$!5 R23VKW
M;1;&T^&W@::^O0IO'4/, >7D/W8Q]/\ $UR8RNZ4.6/Q2T1G4GRJRW9B?&'7
MT6"UT"!AO)$\X'\('"K^/)_ 5E_!F)6\27\I'S+:8'XNO^%=R[G^@]ATKO/@U,%\47D1/+V9(_!U_QK"I0]C@I078B4>6FT8OQ+D,GC
M_4\_PF-1^$:URJ,5D5AP00176_$^ P^/M0)'$BQNON-BC^8-